GX I7

Drug Profile

GX I7

Alternative Names: HyLeukin; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genexine
  • Class Antineoplastics; Immunoglobulin Fc fragments; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin 7 receptor agonists; Lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leucopenia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical intraepithelial neoplasia; Human papillomavirus infections; Leucopenia; Solid tumours

Most Recent Events

  • 28 Mar 2018 Phase-I clinical trials in Solid tumours in South Korea (SC) (Genexine pipeline, March 2018)
  • 05 Mar 2018 Genexine initiates a phase I trial for Solid tumours (Late-stage disease) in South Korea (NCT03478995)
  • 25 Dec 2017 Genexine plans a clinical trial for Solid tumours in South Korea in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top